Where the obesity-drug dollar lands
Loading map…
Companies in this chain
The GLP-1 wave is one of the fastest-growing markets in pharma history. This map shows where the obesity-drug dollar has already landed — each layer's and each company's share of the GLP-1 revenue the chain captures today: the drugmakers, the supply and CDMO layer, the delivery devices, and the adjacent beneficiaries.
How this map is built
Each company's share = its trailing revenue x an estimated 'exposure' fraction to this theme (high / moderate / low), divided by the chain total. It answers who actually captures the spend TODAY, not who might benefit next. Revenue is live from our scan; a few names our universe doesn't cover use a flagged revenue estimate. Exposure bands are qualitative judgements from filings and earnings calls, and they are the part most worth arguing with. This is a snapshot of realized share, not a prediction. The 'signal to watch' is the single leading indicator we'd track for each name.
This is a factual map of supply chain relationships. It is not investment advice, not a recommendation to buy or sell any security, and nothing here accounts for your circumstances. Company classifications change; verify against primary filings before acting.
All Capex Chains · Stock screens · Sub-sectors compared · How the Quant Score works